TICKERNERD
Menu
MCRBMCRBHealthcare · Biotechnology

MCRB Stock Forecast: Seres Therapeutics, Inc. Price Predictions for 2026-2027

Last close, 21 Aug 2026
$4.56
−0.22% on the day

The 2 Wall Street analysts covering Seres Therapeutics, Inc. hold a median 12-month price target of $17 — +272.8% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 50 of 100 as at 22 Aug 2026 — in the upper half.

Market cap
$45.8M
Ticker Nerd rank
50 / 100
Median analyst target
$17
Analysts covering
2
Total return, dividends reinvested
1W
+0.4%
1M
−13.1%
YTD
−69.4%
1Y
−75.1%
From 52W high
−84.1%
From 52W low
+5.1%
$4
$29
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

MCRB stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Seres Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 22 Aug 2026
50 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size
83
Revisions
81
Issuance
74
Quality
51
Accruals
49
Growth
45
Volatility
31
Value
20
Momentum
8

Size (83): Smaller than most of the companies we track.

Momentum (8): The shares have been drifting down relative to others.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

MCRB stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on MCRB, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$5$10$15$20Oct 25Jan 26Apr 26Jul 26MCRBHigh $22Median $17Low $12

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says2 analysts
2 Buy0 Hold0 Sell
Low $12Median $17High $22

The green dot is the last close — the median target sits +272.8% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
23 June 2026HC Wainwright & Co.InitiatesBuy$12
13 Mar 2026Canaccord GenuityMaintainsBuy—
24 Sept 2025Canaccord GenuityMaintainsBuy—
8 May 2025Chardan CapitalDowngradeNeutral—
20 Mar 2025Chardan CapitalMaintainsBuy—
14 Mar 2025Goldman SachsMaintainsSell—
14 Nov 2024Canaccord GenuityMaintainsBuy—
13 Nov 2024Chardan CapitalMaintainsBuy—
24 Oct 2024JP MorganDowngradeUnderweight—
13 Sept 2024Canaccord GenuityMaintainsBuy—
14 Aug 2024Canaccord GenuityMaintainsBuy—
14 Aug 2024Chardan CapitalMaintainsBuy—
7 June 2024Canaccord GenuityMaintainsBuy—
7 June 2024OppenheimerDowngradePerform—
9 May 2024OppenheimerMaintainsOutperform—
8 May 2024Chardan CapitalMaintainsBuy—
6 Mar 2024Chardan CapitalMaintainsBuy—
6 Mar 2024OppenheimerMaintainsOutperform—
16 Jan 2024OppenheimerMaintainsOutperform—
3 Nov 2023Goldman SachsMaintainsSell—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. MCRB appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

MCRB analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
1
Analysts cutting
0
Fundamentals

Seres Therapeutics, Inc. (MCRB) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
11.7×

Cheaper than 55% of US stocks

Price / sales
24.3×

Cheaper than 8% of US stocks

Price / book
1.3×

Cheaper than 64% of US stocks

EV / EBITDA
−1.2×

Cheaper than 67% of US stocks

Growth & margins
Revenue growth (YoY)
105.6%

Higher than 93% of US stocks

Earnings growth (YoY)
—
Gross margin
100.0%

Higher than 99% of US stocks

Operating margin
−2101.4%

Higher than 4% of US stocks

Net margin
−729.4%

Higher than 1% of US stocks

Returns & dividend
Return on equity
−66.6%

Higher than 18% of US stocks

Return on assets
−39.8%

Higher than 10% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

MCRB vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
MCRBSeres Therapeutics, Inc.$45.8M
50
TVGNTevogen, Inc.$43.3M
15
KPTIKaryopharm Therapeutics, Inc.$44.2M
65
EDSAEdesa Biotech, Inc.$42.7M
58
VERUVeru, Inc.$45.0M
40
HOWLWerewolf Therapeutics, Inc.$42.4M
80
CNTXContext Therapeutics, Inc.$45.9M
31

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Seres Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest MCRB news & analysis

Seres Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updates, Including Further Action to Reduce Ongoing Facilities Costs

GlobeNewsWire · 5 Aug 2026neutral

Seres Therapeutics reported its second quarter 2026 financial results and provided business updates. The company announced that 80% of SER-155 recipients achieved immunosuppressive-free clinical response at day 15 for immune checkpoint inhibitor-related enterocolitis in an investigator-sponsored trial, and it is engaging potential partners and seeking capital to advance its SER-155 programs. Seres also agreed to exit additional leased space early to further reduce ongoing facility-related cash costs.

Why it matters — MCRB watchers would care because SER-155's promising irEC data, ongoing partnership and capital-raising efforts, and further facility cost reductions are central to the company's strategy and financial trajectory.

FAQ

Frequently asked questions about MCRB stock

What is the MCRB stock price forecast for 2026-2027?

The 2 Wall Street analysts covering Seres Therapeutics, Inc. have a median 12-month price target of $17, with estimates ranging from $12 to $22. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is MCRB stock a buy right now?

Of the 2 analysts covering Seres Therapeutics, Inc., 2 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Seres Therapeutics, Inc. 50 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank MCRB?

As at 22 Aug 2026, Seres Therapeutics, Inc. ranks 50 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (83 of 100).

Will MCRB stock go up?

No one can know that. What the data says: the median 12-month target from 2 analysts implies +272.8% from the last close, and Ticker Nerd's factor model ranks Seres Therapeutics, Inc. 50 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the MCRB stock forecast for 2030?

No analyst covering Seres Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for MCRB are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $12 to $22 over the next 12 months.

How has MCRB stock performed over the past year?

Seres Therapeutics, Inc. returned -75.1% over the 12 months to 21 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Seres Therapeutics, Inc. do?

Seres Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing live biotherapeutics for serious diseases linked to the human microbiome.

What is the latest news on MCRB?

The most recent item we track (GlobeNewsWire, 5 Aug 2026): "Seres Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updates, Including Further Action to Reduce Ongoing Facilities Costs". Seres Therapeutics reported its second quarter 2026 financial results and provided business updates. The company announced that 80% of SER-155 recipients achieved immunosuppressive-free clinical response at day 15 for immune checkpoint inhibitor-related enterocolitis in an investigator-sponsored trial, and it is engaging potential partners and seeking capital to advance its SER-155 programs. Seres also agreed to exit additional leased space early to further reduce ongoing facility-related cash costs.

Company

About Seres Therapeutics, Inc.

Seres Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing live biotherapeutics for serious diseases linked to the human microbiome. Its current work centers on treatments designed to prevent bacterial bloodstream infections, antimicrobial-resistant infections, and gastrointestinal-related immune disorders in medically vulnerable patients. The company uses rationally selected bacterial consortia and oral capsule formulations to target the mucosal barrier-immune interface and restore healthier microbiome function. Seres Therapeutics’ programs are aimed at high-need areas such as transplant medicine, infectious disease prevention, and inflammatory and immune-mediated conditions. The company is recognized for advancing microbiome-based therapeutics and for its role in bringing the first FDA-approved oral live biotherapeutic to market, while continuing to focus on its current development pipeline and clinical programs.

CEO Mr. Richard N. Kender B.S., M.B.A. · 66 employees · United States · https://www.serestherapeutics.com